| Galapagos and CHDI Continue Collaboration |
| Written by Emilie Anderson |
| Monday, 03 May 2010 15:44 |
|
Galapagos and CHDI Foundation, Inc. enter new five-year collaboration for Huntington's disease therapeutics
Mechelen, Belgium and New York, NY, USA; 29 April 2010 - Galapagos NV (Euronext: GLPG) and CHDI Foundation, Inc., a non-profit virtual biotech pursuing therapies for Huntington's disease, announced today a new five-year collaboration focused on discovering novel drugs for Huntington's disease. Galapagos' service division BioFocus will perform the research and is eligible to receive US$41 million (€31 million) in research fees during the five-year collaboration. |
Except as otherwise noted, content on this site is licensed under a
Creative Commons Attribution 3.0 United States License.
Creative Commons Attribution 3.0 United States License.